Tourmaline Bio Stock (NASDAQ:TRML)

Forecast Revenue Ownership Financials Chart

Previous Close

$47.98

52W Range

$11.56 - $48.27

50D Avg

$40.68

200D Avg

$22.74

Market Cap

$1.23B

Avg Vol (3M)

$925.78K

Beta

1.58

Div Yield

-

TRML Company Profile

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

74

IPO Date

May 07, 2021

Website

TRML Performance

TRML Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-89.73M	$-45.41M	$-19.70M
Net Income	$-73.21M	$-42.12M	$-19.70M
EBITDA	$-89.73M	$-45.38M	$-19.70M
Basic EPS	$-2.89	$-8.87	$-0.97
Diluted EPS	$-2.89	$-8.87	$-0.97

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MAZE	Maze Therapeutics, Inc.
NUVB	Nuvation Bio Inc.
IMTX	Immatics N.V.
ELVN	Enliven Therapeutics, Inc.
SYRE	Spyre Therapeutics, Inc.
TSHA	Taysha Gene Therapies, Inc.
ARDX	Ardelyx, Inc.
WVE	Wave Life Sciences Ltd.
IMNM	Immunome, Inc.
DNTH	Dianthus Therapeutics, Inc.